Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
To the Editor: Scully et al. (Jan. 24 issue) 1 reported that in the HERCULES trial (A Phase III Double-Blind, Randomized, Parallel Group, Multicenter Placebo-Controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura), caplacizumab...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2019-05, Vol.380 (18), p.e32-e32 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e32 |
|---|---|
| container_issue | 18 |
| container_start_page | e32 |
| container_title | The New England journal of medicine |
| container_volume | 380 |
| creator | Yang, Zhao McCaw, Zachary R Yin, Guosheng Olson, Sven R Samuelson-Bannow, Bethany T Scully, Marie Minkue Mi Edou, Jessica Callewaert, Filip |
| description | To the Editor:
Scully et al. (Jan. 24 issue)
1
reported that in the HERCULES trial (A Phase III Double-Blind, Randomized, Parallel Group, Multicenter Placebo-Controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura), caplacizumab accelerated the normalization of platelet counts in patients with acquired thrombotic thrombocytopenic purpura. The survival curves in Figure 1 of their article are initially close, diverge and reconverge multiple times, and finally cross at approximately day 17. The estimated hazard ratio of 1.55 indicates that the time to platelet normalization was shorter with caplacizumab; this conclusion, however, depends on . . . |
| doi_str_mv | 10.1056/NEJMc1902336 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2218999510</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2218389609</sourcerecordid><originalsourceid>FETCH-LOGICAL-c489t-b4d552eac5132f2cf29e4067fbfb3902902d543d31f3fcb8abebce0dd961ae013</originalsourceid><addsrcrecordid>eNqN0U1LwzAYB_AgipvTm2cZ6MGD1by1aw4exphvzJfDPJckTbCjabqkOcxPb3SbiHgwBBLCjz_PkweAYwQvEUyzq6fpw6NEDGJCsh3QRykhCaUw2wV9CHGe0BEjPXDg_QLGhSjbBz2CIMU5TfvgesLbmsvqPRguhtq64VguQ-VUOZy_OWuE7Sq5vcpVZ1vVxIeX4Nrg-CHY07z26mhzDsDrzXQ-uUtmz7f3k_EskTRnXSJomaZYcZkigjWWGjMVKxxpoQWJlcddppSUBGmipci5UEIqWJYsQ1xBRAbgfJ3bOrsMyneFqbxUdc0bZYMvMEY5YyxF8L-U5Fmkp7_owgbXxEa-FMlZBllUF2slnfXeKV20rjLcrQoEi88JFD8nEPnJJjQIo8pvvP3yCM7WwBhfNGph_s75AFGViro</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2218389609</pqid></control><display><type>article</type><title>Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Yang, Zhao ; McCaw, Zachary R ; Yin, Guosheng ; Olson, Sven R ; Samuelson-Bannow, Bethany T ; Scully, Marie ; Minkue Mi Edou, Jessica ; Callewaert, Filip</creator><creatorcontrib>Yang, Zhao ; McCaw, Zachary R ; Yin, Guosheng ; Olson, Sven R ; Samuelson-Bannow, Bethany T ; Scully, Marie ; Minkue Mi Edou, Jessica ; Callewaert, Filip</creatorcontrib><description>To the Editor:
Scully et al. (Jan. 24 issue)
1
reported that in the HERCULES trial (A Phase III Double-Blind, Randomized, Parallel Group, Multicenter Placebo-Controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura), caplacizumab accelerated the normalization of platelet counts in patients with acquired thrombotic thrombocytopenic purpura. The survival curves in Figure 1 of their article are initially close, diverge and reconverge multiple times, and finally cross at approximately day 17. The estimated hazard ratio of 1.55 indicates that the time to platelet normalization was shorter with caplacizumab; this conclusion, however, depends on . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMc1902336</identifier><identifier>PMID: 31042845</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>ADAMTS13 Protein ; Humans ; Platelets ; Purpura, Thrombotic Thrombocytopenic ; Single-Domain Antibodies ; Thrombotic thrombocytopenic purpura</subject><ispartof>The New England journal of medicine, 2019-05, Vol.380 (18), p.e32-e32</ispartof><rights>Copyright © 2019 Massachusetts Medical Society. All rights reserved.</rights><rights>Copyright Massachusetts Medical Society May 2, 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c489t-b4d552eac5132f2cf29e4067fbfb3902902d543d31f3fcb8abebce0dd961ae013</citedby><cites>FETCH-LOGICAL-c489t-b4d552eac5132f2cf29e4067fbfb3902902d543d31f3fcb8abebce0dd961ae013</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMc1902336$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2218389609?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,777,781,2746,2747,26084,27905,27906,52363,54045,64364,64366,64368,72218</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31042845$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Zhao</creatorcontrib><creatorcontrib>McCaw, Zachary R</creatorcontrib><creatorcontrib>Yin, Guosheng</creatorcontrib><creatorcontrib>Olson, Sven R</creatorcontrib><creatorcontrib>Samuelson-Bannow, Bethany T</creatorcontrib><creatorcontrib>Scully, Marie</creatorcontrib><creatorcontrib>Minkue Mi Edou, Jessica</creatorcontrib><creatorcontrib>Callewaert, Filip</creatorcontrib><title>Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor:
Scully et al. (Jan. 24 issue)
1
reported that in the HERCULES trial (A Phase III Double-Blind, Randomized, Parallel Group, Multicenter Placebo-Controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura), caplacizumab accelerated the normalization of platelet counts in patients with acquired thrombotic thrombocytopenic purpura. The survival curves in Figure 1 of their article are initially close, diverge and reconverge multiple times, and finally cross at approximately day 17. The estimated hazard ratio of 1.55 indicates that the time to platelet normalization was shorter with caplacizumab; this conclusion, however, depends on . . .</description><subject>ADAMTS13 Protein</subject><subject>Humans</subject><subject>Platelets</subject><subject>Purpura, Thrombotic Thrombocytopenic</subject><subject>Single-Domain Antibodies</subject><subject>Thrombotic thrombocytopenic purpura</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqN0U1LwzAYB_AgipvTm2cZ6MGD1by1aw4exphvzJfDPJckTbCjabqkOcxPb3SbiHgwBBLCjz_PkweAYwQvEUyzq6fpw6NEDGJCsh3QRykhCaUw2wV9CHGe0BEjPXDg_QLGhSjbBz2CIMU5TfvgesLbmsvqPRguhtq64VguQ-VUOZy_OWuE7Sq5vcpVZ1vVxIeX4Nrg-CHY07z26mhzDsDrzXQ-uUtmz7f3k_EskTRnXSJomaZYcZkigjWWGjMVKxxpoQWJlcddppSUBGmipci5UEIqWJYsQ1xBRAbgfJ3bOrsMyneFqbxUdc0bZYMvMEY5YyxF8L-U5Fmkp7_owgbXxEa-FMlZBllUF2slnfXeKV20rjLcrQoEi88JFD8nEPnJJjQIo8pvvP3yCM7WwBhfNGph_s75AFGViro</recordid><startdate>20190502</startdate><enddate>20190502</enddate><creator>Yang, Zhao</creator><creator>McCaw, Zachary R</creator><creator>Yin, Guosheng</creator><creator>Olson, Sven R</creator><creator>Samuelson-Bannow, Bethany T</creator><creator>Scully, Marie</creator><creator>Minkue Mi Edou, Jessica</creator><creator>Callewaert, Filip</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20190502</creationdate><title>Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura</title><author>Yang, Zhao ; McCaw, Zachary R ; Yin, Guosheng ; Olson, Sven R ; Samuelson-Bannow, Bethany T ; Scully, Marie ; Minkue Mi Edou, Jessica ; Callewaert, Filip</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c489t-b4d552eac5132f2cf29e4067fbfb3902902d543d31f3fcb8abebce0dd961ae013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>ADAMTS13 Protein</topic><topic>Humans</topic><topic>Platelets</topic><topic>Purpura, Thrombotic Thrombocytopenic</topic><topic>Single-Domain Antibodies</topic><topic>Thrombotic thrombocytopenic purpura</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Zhao</creatorcontrib><creatorcontrib>McCaw, Zachary R</creatorcontrib><creatorcontrib>Yin, Guosheng</creatorcontrib><creatorcontrib>Olson, Sven R</creatorcontrib><creatorcontrib>Samuelson-Bannow, Bethany T</creatorcontrib><creatorcontrib>Scully, Marie</creatorcontrib><creatorcontrib>Minkue Mi Edou, Jessica</creatorcontrib><creatorcontrib>Callewaert, Filip</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Zhao</au><au>McCaw, Zachary R</au><au>Yin, Guosheng</au><au>Olson, Sven R</au><au>Samuelson-Bannow, Bethany T</au><au>Scully, Marie</au><au>Minkue Mi Edou, Jessica</au><au>Callewaert, Filip</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2019-05-02</date><risdate>2019</risdate><volume>380</volume><issue>18</issue><spage>e32</spage><epage>e32</epage><pages>e32-e32</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>To the Editor:
Scully et al. (Jan. 24 issue)
1
reported that in the HERCULES trial (A Phase III Double-Blind, Randomized, Parallel Group, Multicenter Placebo-Controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura), caplacizumab accelerated the normalization of platelet counts in patients with acquired thrombotic thrombocytopenic purpura. The survival curves in Figure 1 of their article are initially close, diverge and reconverge multiple times, and finally cross at approximately day 17. The estimated hazard ratio of 1.55 indicates that the time to platelet normalization was shorter with caplacizumab; this conclusion, however, depends on . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>31042845</pmid><doi>10.1056/NEJMc1902336</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2019-05, Vol.380 (18), p.e32-e32 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2218999510 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | ADAMTS13 Protein Humans Platelets Purpura, Thrombotic Thrombocytopenic Single-Domain Antibodies Thrombotic thrombocytopenic purpura |
| title | Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T10%3A20%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Caplacizumab%20for%20Acquired%20Thrombotic%20Thrombocytopenic%20Purpura&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Yang,%20Zhao&rft.date=2019-05-02&rft.volume=380&rft.issue=18&rft.spage=e32&rft.epage=e32&rft.pages=e32-e32&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMc1902336&rft_dat=%3Cproquest_cross%3E2218389609%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2218389609&rft_id=info:pmid/31042845&rfr_iscdi=true |